Sp1/Sp3 binding is associated with cell-specific expression of the glucose-dependent insulinotropic polypeptide receptor gene

American Journal of Physiology - Endocrinology and Metabolism

Volumn 290, Issue 6, 2006, Pages

  Boylan, Michael O ^a   Jepeal, Lisa I ^a   Wolfe, M Michael ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Chromatin immunoprecipitation assay; Gastric inhibitory polypeptide; Insulinoma; Rat 2 cells; RIN38 cells; Transcription factors

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ANIMAL CELL; ARTICLE; CELL SPECIFICITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA FLANKING REGION; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; IMMUNOREACTIVITY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; RAT;

ANIMALS; BASE SEQUENCE; BINDING SITES; CONSERVED SEQUENCE; GASTRIC INHIBITORY POLYPEPTIDE; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RATS; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 33744906739     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00535.2005     Document Type: Article

References (52)

1. Aino H, Hashimoto H, Ogawa N, Nishino A, Yamamoto K, Nogi H, Nagata S, and Baba A. Structure of the gene encoding the mouse pituitary adenylate cyclase-activating polypeptide receptor. Gene 164: 301-304, 1995.
2. Alimov AP, Langub MC, Malluche HH, and Koszewski NJ. Sp3/Sp1 in the parathyroid gland: identification of an Sp1 deoxyribonucleic acid element in the parathyroid hormone promoter. Endocrinology 144: 3138-3147, 2003.
3. Azizkhan JC, Jensen DE, Pierce AJ, and Wade M. Transcription from TATA-less promoters: dihydrofolate reductase as a model. Crit Rev Eukaryot Gene Expr 3: 229-254, 1993.
4. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I, Knox RJ, Plumb JA, and Keith WN. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22: 370-380, 2003.
5. Boylan MO, Jepeal LI, and Wolfe MM. Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene. Peptides 20: 219-228, 1999.
6. Brown JC and Dryburgh JR. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 49: 867-872, 1971.
7. Buggy J, Hull J, and Yoo-Warren H. Isolation and structural analysis of the 5′ flanking region of the gene encoding the human glucagon receptor. Biochem Biophys Res Commun 208: 339-344, 1995.
8. Cissell MA, Zhao L, Sussel L, Henderson E, and Stein R. Transcription factor occupancy of the insulin gene in vivo. Evidence for direct regulation by Nkx22. J Biol Chem 278: 751-756, 2003.
9. Clem AL, Hamid T, and Kakar SS. Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene 322: 113-121, 2003.
10. Cook T, Gebelein B, and Urrutia R. Sp1 and its likes: biochemical and functional predictions for a growing family of zinc finger transcription factors. Ann NY Acad Sci 880: 94-102, 1999.
11. Courey AJ and Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 55: 887-898, 1988.
12. Dignam JD, Lebovitz RM, and Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983.
13. Dufau ML, Tsai-Morris CH, Hu ZZ, and Buczko E. Structure and regulation of the luteinizing hormone receptor gene. J Steroid Biochem Mol Biol 53: 283-291, 1995.
14. Dupre J, Greenidge N, McDonald TJ, Ross SA, and Rubinstein D. Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide. Metabolism 25: 1197-1199, 1976.
15. Dupre J, Ross SA, Watson D, and Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37: 826-828, 1973.
16. Galehshahi FS, Goke B, and Lankat-Buttgereit B. A novel silencer element repressing expression of the GLP-1 receptor gene in fibroblasts and pancreatic A-cells, but not in pancreatic B- and D-cells. Peptides 21: 1169-1176, 2000.
17. Gerrish K, Cissell MA, and Stein R. The role of hepatic nuclear factor 1α and PDX-1 in transcriptional regulation of the pdx-1 gene. J Biol Chem 276: 47775-47784, 2001.
18. Holst JJ, Gromada J, and Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40: 984-986, 1997.
19. Hromas R, Collins SJ, Hickstein D, Raskind W, Deaven LL, O'Hara P, Hagen FS, and Kaushansky K. A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J Biol Chem 266: 14183-14187, 1991.
20. Innis MA and Gelfand DH. Optimization of PCRs. In: PCR Protocols: A Guide to Methods and Application. San Diego, CA: Academic, 1990.
21. Jepeal LI, Boylan MO, and Wolfe MM. Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line. Regul Pept 113: 139-147, 2003.
22. Jones KA, Yamamoto KR, and Tjian R. Two distinct transcription factors bind to the HSV thymidine kinase promoter in vitro. Cell 42: 559-572, 1985.
23. Kingsley C and Winoto A. Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol 12: 4251-4261, 1992.
24. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, and Sestoft L. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56: 1306-1312, 1983.
25. Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R, and et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion - a new cause of Cushing's syndrome. N Engl J Med 327: 974-980, 1992.
26. Lacroix A, Ndiaye N, Tremblay J, and Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 22: 75-110, 2001.
27. Lankat-Buttgereit B and Goke B. Cloning and characterization of the 5′ flanking sequences (promoter region) of the human GLP-1 receptor gene. Peptides 18: 617-624, 1997.
28. Larsen PJ, Fledelius C, Knudsen LB, and Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50: 2530-2539, 2001.
29. Le Mee S, Fromigue O, and Marie PJ. Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. Exp Cell Res 302: 129-142, 2005.
30. Loots GG and Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res 32: W217-W221, 2004.
31. Lyko F, Ramsahoye BH, and Jaenisch R. DNA methylation in Drosophila melanogaster. Nature 408: 538-540, 2000.
32. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, and Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50: 1004-1011, 2001.
33. Mazzaferri EL, Starich GH, Lardinois CK, and Bowen GD. Gastric inhibitory polypeptide responses to nutrients in Caucasians and American Indians with obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 61: 313-321, 1985.
34. McCuaig KA, Lee HS, Clarke JC, Assar H, Horsford J, and White JH. Parathyroid hormone/parathyroid hormone related peptide receptor gene transcripts are expressed from tissue-specific and ubiquitous promoters. Nucleic Acids Res 23: 1948-1955, 1995.
35. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, and Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742, 2002.
36. Moorefield KS, Fry SJ, and Horowitz JM. Sp2 DNA binding activity and trans-activation are negatively regulated in mammalian cells. J Biol Chem 279: 13911-13924, 2004.
37. Osei K, Falko JM, O'Dorisio TM, Fields PG, and Bossetti B. Gastric inhibitory polypeptide responses and glucose turnover rates after natural meals in type II diabetic patients. J Clin Endocrinol Metab 62: 325-330, 1986.
38. Ottlecz A, Samson WK, and McCann SM. The effects of gastric inhibitory polypeptide (GIP) on the release of anterior pituitary hormones. Peptides 6: 115-119, 1985.
39. Pederson RA, Schubert HE, and Brown JC. The insulinotropic action of gastric inhibitory polypeptide. Can J Physiol Pharmacol 53: 217-223, 1975.
40. Pei L. Genomic organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene. J Biol Chem 273: 5219-5225, 1998.
41. Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, and Mahoudeau J. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 327: 981-986, 1992.
42. Sreedharan SP, Huang JX, Cheung MC, and Goetzl EJ. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA 92: 2939-2943, 1995.
43. Stocco DM and Clark BJ. Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 17: 221-244, 1996.
44. 1 and a wortmannin-sensitive signalling pathway. Biochem Biophys Res Commun 224: 369-374, 1996.
45. Tseng CC, Boylan MO, Jarboe LA, Usdin TB, and Wolfe MM. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am J Physiol Endocrinol Metab 270: E661-E666, 1996.
46. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, and Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98: 2440-2445, 1996.
47. Tseng CC, Zhang XY, and Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol Endocrinol Metab 276: E1049-E1054, 1999.
48. Usdin TB, Mezey E, Button DC, Brownstein MJ, and Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133: 2861-2870, 1993.
49. Villar HV, Fender HR, Rayford PL, Bloom SR, Ramus NI, and Thompson JC. Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP). Ann Surg 184: 97-102, 1976.
50. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, and Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95: 417-421, 1995.
51. Weir GC. Glucagon-like peptide-1 (GLP-1): a piece of the incretin puzzle. J Clin Invest 95: 1, 1995.
52. Wingender E. Recognition of regulatory regions in genomic sequences. J Biotechnol 35: 273-280, 1994.